{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:48:14Z","timestamp":1759333694488,"version":"build-2065373602"},"reference-count":4,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jaad.2022.04.067","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T15:37:24Z","timestamp":1654789044000},"page":"e277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to Wang et\u00a0al's \u201cAnalysis of utilization, cost and, prescription trends of onychomycosis medications among Medicare patients\u201d"],"prefix":"10.1016","volume":"88","author":[{"given":"Michael J.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2022.04.067_bib1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2021.10.007","article-title":"Analysis of utilization, cost and, prescription trends of onychomycosis medications among Medicare patients","volume":"86","author":"Wang","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.04.067_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: treatment and prevention of recurrence","volume":"80","author":"Lipner","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2022.04.067_bib3","first-page":"1076","article-title":"Therapeutic recommendations for the treatment of toenail onychomycosis in the US","volume":"20","author":"Lipner","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2022.04.067_bib4","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/jdv.16394","article-title":"Onychomycosis: a review","volume":"34","author":"Gupta","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222009732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222009732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:26:34Z","timestamp":1759274794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222009732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0190962222009732"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.04.067","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to Wang et\u00a0al's \u201cAnalysis of utilization, cost and, prescription trends of onychomycosis medications among Medicare patients\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.06.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}